Spermosens AB

SPERM.ST

Medical - Diagnostics & Research · Healthcare

Price

kr 0.01

+0.00 (+17.95%)

Market Cap

kr 29.2M

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+8557.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 29.3M (2021) → 2.54B (2025)

Winston Score History

The full picture

Spermosens AB is a small Swedish medical technology company focused on developing diagnostic tools for male fertility testing. Its core product is a biosensor-based device designed to assess sperm quality, targeting fertility clinics, hospitals, and potentially at-home users who need faster and more accessible sperm analysis. The company operates in the diagnostics and reproductive health industry.

Spermosens generates little to no revenue at this stage, as it appears to be in early development, which explains its zero gross margin and negative returns on capital. It is based in Sweden and operates at a very small scale, with a market cap near zero. The company's potential moat would come from proprietary biosensor technology and any patents protecting its testing method. The key risk is straightforward: the company must successfully develop, clinically validate, and commercialize its product before it runs out of funding, which is a significant challenge for any pre-revenue medical device startup.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+100.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

kr 6M/ year

↑ Rising (+19% vs prior year)

R&D investment increasing — building for the future

Insider Activity

23.7%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

kr 2M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Spermosens AB has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-34.5%

Weak — -34.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial